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Summary
Background Continuing rises in tuberculosis notiﬁ cations in the UK are attributable to cases in foreign-born 
immigrants. National guidance for immigrant screening is hampered by a lack of data about the prevalence of, and 
risk factors for, latent tuberculosis infection in immigrants. We aimed to determine the prevalence of latent infection 
in immigrants to the UK to deﬁ ne which groups should be screened and to quantify cost-eﬀ ectiveness.
Methods In our multicentre cohort study and cost-eﬀ ectiveness analysis we analysed demographic and test results 
from three centres in the UK (from 2008 to 2010) that used interferon-γ release-assay (IGRA) to screen immigrants 
aged 35 years or younger for latent tuberculosis infection. We assessed factors associated with latent infection by use 
of logistic regression and calculated the yields and cost-eﬀ ectiveness of screening at diﬀ erent levels of tuberculosis 
incidence in immigrants’ countries of origin with a decision analysis model.
Findings Results for IGRA-based screening were positive in 245 of 1229 immigrants (20%), negative in 982 (80%), and 
indeterminate in two (0·2%). Positive results were independently associated with increases in tuberculosis incidence 
in immigrants’ countries of origin (p=0·0006), male sex (p=0·046), and age (p<0·0001). National policy thus far 
would fail to detect 71% of individuals with latent infection. The two most cost-eﬀ ective strategies were to screen 
individuals from countries with a tuberculosis incidence of more than 250 cases per 100 000 (incremental cost-
eﬀ ectiveness ratio [ICER] was £17 956 [£1=US$1·60] per prevented case of tuberculosis) and at more than 150 cases 
per 100 000 (including immigrants from the Indian subcontinent), which identiﬁ ed 92% of infected immigrants and 
prevented an additional 29 cases at an ICER of £20 819 per additional case averted.
Interpretation Screening for latent infection can be implemented cost-eﬀ ectively at a level of incidence that identiﬁ es 
most immigrants with latent tuberculosis, thereby preventing substantial numbers of future cases of active 
tuberculosis.
Funding Medical Research Council and Wellcome Trust.
Introduction
Although tuberculosis prevails in mainly high-burden 
developing countries, cases in immigrants in many low-
incidence countries are increasing substantially.1 This 
changing pattern of disease is clear in the UK where, 
between 1998 and 2009, tuberculosis notiﬁ cations have 
risen by 46%, from 6167 cases to 9040, with much of this 
rise fuelled by the 98% increase in cases from overseas.2,3 
These individuals account for nearly three-quarters of all 
tuberculosis notiﬁ cations in the UK with an incidence 
that is 20 times higher than in UK-born individuals 
(89 cases per 100 000 people per year vs 4 per 100 000).3
The evolving epidemiology in high-income countries is 
driven mostly by migration of individuals from countries 
with a high burden of disease, such as sub-Saharan Africa 
and the Indian subcontinent,4,5 and by the reactivation of 
latent tuberculosis infection that was acquired before 
migration.6 These factors result in a high incidence of 
tuberculosis in immigrants in the ﬁ rst 2–5 years after 
migration (with about 50% of foreign-born cases 
presenting in the ﬁ rst 5 years after migration), which 
then decreases over time.7,8
Changes in incidence have renewed interest in 
tuberculosis screening of immigrants.9 Data in several 
high-income countries suggest that screening for latent 
infection is highly variable—both in which immigrants 
are screened, and how they are screened.10 UK national 
policy speciﬁ es port-of-entry identiﬁ cation and screening 
with chest radiographs for immigrants from countries 
with a tuberculosis incidence of more than 40 cases 
per 100 000 population per year who intend to stay in the 
UK for more than 6 months. The aim of this initial 
screening is to detect active pulmonary tuberculosis,11 
and results determine the subsequent actions taken by 
the individual’s local tuberculosis services.
Actions should be undertaken in line with national 
guidelines for tuberculosis control.12 For most immigrants 
with normal chest radiographs, since 2006, the National 
Institute for Health and Clinical Excellence (NICE) 
recommends that local tuberculosis services should screen 
speciﬁ c subgroups of new entrants for latent infection, 
including children aged less than 16 years from countries 
with a tuberculosis incidence or more than 40 per 100 000 
per year, and 16–35-year-olds from either sub-Saharan 
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countries or from those with a disease incidence of more 
than 500 per 100 000 per year. Individuals older than 
35 years are not screened because the risks of 
chemoprophylaxis outweigh the potential beneﬁ ts.12
The rationale supporting this screening approach 
remains unclear, especially because data are scarce for 
the prevalence of latent infection in new immigrants as 
measured by interferon-γ release assays (IGRAs).13 
Furthermore, although NICE’s recommen dation for 
the two-step method of screening (ie, tuberculin skin-
test plus conﬁ rmatory IGRA) has been adopted in most 
European countries, the USA,14 and many centres in 
the UK increasingly use one-step IGRA testing to 
screen for latent infection,13,15 probably because of this 
test’s high speciﬁ city.16–18 Additional reasons for the use 
of the one-step test include evidence that IGRAs might 
be able to predict the development of active tuberculosis 
from latent infection,19–28 and uncertainty about the 
optimum cutoﬀ  for a positive skin test in the context of 
previous BCG vaccination.29 We did this multicentre 
cohort study to compute yields from, and cost-
eﬀ ectiveness of, screening for latent infection at 
diﬀ erent thresholds in relation to incidence of 
tuberculosis in immigrants’ countries of origin.
Methods
Study design and participants
We did this prospective multicentre study and cost-
eﬀ ectiveness analysis of immigrant screening in three 
centres in the UK: Westminster, London; Leeds, 
Yorkshire; and Blackburn, Lancashire. Together these 
centres serve 1·6 million people30 of whom 6·5% 
(IQR 4·3%–9·9%) are foreign born.31 Between 2007 
and 2009, the average 3-year notiﬁ cations in these centres 
ranged from 54 to 126, and incidence varied from 16 to 
33 cases per 100 000 population per year.32
Participants were foreign-born new entrants (arrival 
within the past 5 years) who were aged 35 years or 
younger and who were referred for and underwent 
tuberculosis screening between Jan 1, 2008, and 
July 31, 2010. Referrals to these centres were made 
either through port-of-entry screening systems, health-
protection units, or after registration with primary-care 
services. Ethical approval was not needed because the 
study used fully anonymised observational data that 
were obtained as part of an assessment of routine 
clinical service.
Screening and management
We ﬁ rst screened immigrants who attended the centres 
with a symptom questionnaire followed by one-step 
IGRA (QuantiFERON-TB Gold In-Tube. Carnegie, 
Cellestis,  Australia), a whole blood ELISA, containing 
ESAT-6 (early secretory antigenic target-6), CFP-10 
(culture ﬁ ltrate protein-10), and TB7.7 (Rv2654), which 
Panel 1: Model assumptions of the health economic model
• Immigrants are screened for latent tuberculosis infection at the start of the 20-year 
time line
• All IGRA results are determinate and no repeat testing is needed
• At the time of screening the immigrants there are no prevalent cases of active 
tuberculosis in the cohort
• There are no HIV-coinfected individuals in the cohort
• All active cases are caused by a tuberculosis strain that is fully drug sensitive
• In individuals with latent infection who are treated with chemoprophylaxis, a 3-month 
course of rifampicin and isoniazid has the same eﬀ ectiveness as 6 months of isoniazid
• Individuals who start chemoprophylaxis and subsequently develop drug-induced liver 
injury that does not resolve are assumed to complete only 4 weeks of therapy, which 
aﬀ ords no reduction in the risk of progressing to active infection
• An individual with latent tuberculosis who has completed successful chemoprophylaxis 
is assumed to have cleared the infection with Mycobacterium tuberculosis and will not 
experience any further outcomes in the time course of the model
• An individual who does not have latent infection on arrival in the UK does not become 
infected during the period of the model
• Data for the test performance of the IGRA were based on the most recent meta-analysis 
obtained from meta-analyses in which sensitivity was calculated with culture-conﬁ rmed 
active tuberculosis as the reference standard; speciﬁ city was calculated from 
BCG-vaccinated individuals at low risk of infection
• All individuals who are diagnosed with active tuberculosis are assumed to accept 
treatment for active infection and to complete the 6-month course of drugs
IGRA= interferon-γ release assays.
Figure 1: Study ﬂ ow diagram
*Data for non-attendees available for only two of the three centres in the study.
1633 invited to be screened
1364 attended
3 refused screening
*269 did not attend
1361 screened
132 excluded from  
analysis:  
57 resident in UK>5 years  
60 duration in UK unknown 
5 cases of active tuberculosis
diagnosed  
2 with past history of
tuberculosis  
5 country of origin not  
recorded  
1 IGRA result missing  
1 demographic data  
missing  
1 UK born 
1229 included in ﬁnal analysis
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was done in accordance with the manufacturer’s 
instructions. Results were positive, negative, or 
indeterminate, dependent on the manufacturer’s criteria. 
A meta-analysis33 of the eﬀ ectiveness of the 
QuantiFERON-TB Gold In-Tube suggests that sensitivity 
is 84% and speciﬁ city is 99%. Immigrants who were 
symptomatic or who had a positive IGRA result were 
referred for chest radiography and further clinical 
assessment to discount active tuberculosis.12
We deﬁ ned latent tuberculosis infection as immigrants 
with a positive IGRA and normal chest radiography in 
the absence of any clinical features that would suggest 
active disease.34 Immigrants who were diagnosed with 
latent infection were oﬀ ered chemoprophylaxis with 
either 3 months of rifampicin and isoniazid, or 6 months 
of isoniazid, in accordance with UK guidelines,12 
dependent on clinician and patient preference.
Statistical analysis
We obtained data for demographics (age categorised as 
<16 years, 16–25 years, or 26–35 years, and sex), BCG 
vaccination status (ascertained through documentary 
evidence, reliable history of vaccination, or a 
characteristic scar35), and country of origin. From 
reported country of origin, we further classiﬁ ed data 
into region of origin (Europe and the Americas, Middle 
East and north Africa, other Asia, Indian subcontinent, 
or sub-Saharan Africa) and we took tuberculosis 
incidence in the country (categorised as 0 cases per 
100 000/year–50 cases per 100 000/year; 51/100 00–
150/100 000; 151/100 000–250/100 000; 251/100 000–
350/100 000, and ≥350/100 000) from WHO’s 2009 
global report on tuberculosis.36
Number in total 
cohort (n=1229)
Number of IGRA-positive 
individuals/total number 
tested (n=245)
Unadjusted OR 
(95% CI)
p value Adjusted OR 
(95% CI)
p value
Age (years)
<16* 36 (3%) 7/36 (19%) 1 0·0051† 1‡ <0·0001§
16–25 589 (48%) 86/589 (15%) 0·7 (0·3–1·7) .. 0·9 (0·4–2·1) ..
26–35 604 (49%) 152/604 (25%) 1·4 (0·6–3·2) .. 1·7 (0·7–4·1) ..
Sex
Female 629 (51%) 109/629(17%) 1 0·02 1¶ 0·046
Male 600 (49%) 136/600 (23%) 1·4 (1·1–1·9) .. 1·3 (1·0–1 8) ..
Origin||
Europe, Americas 50 (4%) 2/50 (4%) 1 0·0011 ·· ··
Middle East, North Africa 26 (2%) 1/26 (4%) 1·0 (0·1–11·1) .. ·· ··
Other Asia 162 (13%) 29/162 (18%) 5·2 (1·2–22·8) .. ·· ··
Indian subcontinent 740 (60%) 144/740 (20%) 5·8 (1·4–24·1) .. ·· ··
Sub-Saharan Africa 251 (20%) 69/251 (28%) 9·1 (2·2–38·5) .. ·· ··
Incidence of tuberculosis in country of origin (cases per 100 000 population per year)||
0–50 32 (3%) 1/32 (3%) 1 <0·0001† 1** 0·0006
51–150 150 (12%) 19/150 (13%) 4·5 (0·60–34·9) .. 4·5 (0·60–35·3) ..
151–250 835 (68%) 164/835 (20%) 7·6 (1·0–55·9) .. 7·9 (1·1–58·3) ..
251–350 139 (11%) 41/139 (30%) 13·0 (1·7–98·2) .. 13·3 (1.8–101·5) ..
>350 73 (6%) 20/73 (27%) 11·7 (1·5–91·5) .. 13·1 (1·7–102·7) ..
BCG vaccinated?
No 113 (17%) 16/113 (14%) 1 0·17 ·· ··
Yes 544 (83%) 107/544 (20%) 1·5 (0·8–2·6) .. ·· ··
IGRA=interferon-γ release assay. OR=odds ratio. *Of the 36 individuals aged <16 years, one (2·8%) was aged ≤4 years, one (2·8%) was 5–9 years, and 34 (94·4%) were 
10–15 years. †χ² p for trend. ‡Mutually adjusted for sex and incidence of tuberculosis in country of origin. §p value denotes overall eﬀ ect of age in the model. ¶Mutually 
adjusted for age and tuberculosis incidence in country of origin. ||Region of origin and tuberculosis incidence in country of origin were strongly correlated; therefore, in the 
multivariate analysis, region of origin was left out. **Mutually adjusted for age and sex.
Table 1: Demographics of cohort and risk factors associated with IGRA positivity in immigrants 
Figure 2: Proportion of immigrants aged 35 years or younger who tested 
IGRA positive according to tuberculosis incidence in their country of origin
IGRA=interferon-γ release assays. Bars=95% CIs.
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Continuous data were summarised with median and 
IQR, and were compared with the non-parametric Mann-
Whitney U-test. Categorical responses were expressed as 
a simple descriptive percentage with 95% CIs, and 
comparisons were made with Pearson χ² or Fisher’s 
exact test as appropriate. We calculated yield of latent 
infection  as the proportion of individuals who were 
IGRA positive; indeterminate results were included in 
the denominator when calculating IGRA-positivity. We 
assessed univariate associations of the presence of latent 
infection with age, sex, region of origin, tuberculosis 
incidence in country of origin, and BCG status using 
logistic regression, and reported as crude odds ratios 
(OR) and 95% CIs. We then calculated adjusted ORs by 
mutually adjusting in a multivariate logistic regression 
for age, sex, and tuberculosis incidence in country of 
origin (to account for potential confounders) with the 
same categories outlined above. We did not include BCG 
status in the multivariate model because of the high 
proportion of missing values. 
To assess the diﬀ erent thresholds of incidence 
screening we calculated, at every incidence level cutoﬀ , 
the absolute number of immigrants needing to be 
screened, the yield for latent tuberculosis infection, and 
the proportion of individuals with latent infection who 
would not be detected at particular thresholds of 
screening. Because screening of children is a priority in 
tuberculosis control, and because the number of child 
immigrants younger than 16 years is small, we also 
considered screening all children irrespective of 
tuberculosis incidence in their country of origin.
Analyses used STATA version 9.2. All tests were two- 
tailed and p values less than 0·05 were regarded as 
signiﬁ cant.
Economic analysis
Economic analysis was done from a UK National Health 
Service perspective to consider two main questions 
related to use of a one-step IGRA strategy over 20 years. 
What are the costs of screening at diﬀ erent incidence 
thresholds? And is screening at speciﬁ c thresholds cost 
eﬀ ective and, if so, which threshold if any is the most 
cost eﬀ ective? We developed a decision tree 
(webappendix pp 12–15) to simulate the clinical (number 
of cases of active tuberculosis), and economic outcomes 
of screening a hypothetical cohort of 10 000 new 
immigrants aged 35 years and younger for latent infection 
over a 20-year timeline.
We considered screening using QuantiFERON-TB 
Gold In-Tube alone and varying the incidence threshold 
in the country of origin at which individuals became 
eligible for screening. At each threshold cutoﬀ , we 
assessed the number of immigrants who would be 
eligible for screening, the number who would be IGRA-
positive, and the number of IGRA-positives that would 
be undetected compared with screening of the whole 
cohort. The decision tree was constructed and analysed 
with Microsoft Excel 2007 and TreeAge Pro 2011 (Tree 
Age Software, Williamstown, MA, USA). Panel 1 shows 
the model assumptions. For descriptions and discussion 
of the decision model, sources for the associated costs (in 
pounds sterling) and input probabilities and parameters, 
how cost-eﬀ ectiveness was measured, and ranges for 
sensitivity analysis see webappendix (pp 2–9).
Role of the funding source
The funding sources played no part in the study design, 
data analysis, writing of the manuscript or decision to 
submit for publication. None of the investigators were 
paid to write this article by a pharmaceutical company or 
other agency. The corresponding author had full access 
to the data and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Recruitment into the study is outlined in ﬁ gure 1. Table 1 
shows the demographics of the screened population 
(n=1229). 1193 (97%) of screened immigrants were mostly 
young adults (aged 16–35 years) and attendees were less 
Number 
tested
Number 
positive
Yield at 
incidence 
level*
Proportion of all latent 
infection identiﬁ ed if 
threshold set at this level
Aged <16 years†
Screen ≥500 and sub-Saharan Africa 16 4 25·0% 57·1%
Screen ≥500 6 2 33·3% 28·6%
Screen ≥450 6 2 33·3% 28·6%
Screen ≥400 6 2 33·3% 28·6%
Screen ≥350 7 2 28·6% 28·6%
Screen ≥300 12 2 16·7% 28·6%
Screen ≥250 15 3 20·0% 42·9%
Screen ≥200 23 4 17·4% 57·1%
Screen ≥150 34 6 17·7% 85·7%
Screen ≥100 34 6 17·7% 85·7%
Screen ≥40‡ 36 7 19·4% 100%
Screen all 36 7 19·4% 100%
16–35 years†
Screen ≥500 and sub-Saharan Africa‡ 235 65 27·7% 27·3%
Screen ≥500 46 12 26·1% 5·0%
Screen ≥450 54 13 24·1% 5·5%
Screen ≥400 55 13 23·6% 5·5%
Screen ≥350 66 18 27·3% 7·6%
Screen ≥300 135 38 28·2% 15·9%
Screen ≥250 197 58 29·4% 24·4%
Screen ≥200 668 127 19·0% 53·4%
Screen ≥150 1013 219 21·6% 92·0%
Screen ≥100 1068 222 20·8% 93·3%
Screen ≥40 1180 238 20·2% 100%
Screen all 1193 238 20·0% 100%
*Proportion of those tested giving a positive result. †Per 100 000 population per year. ‡Present NICE guidance.
Table 2: Yields for latent tuberculosis infection (deﬁ ned as positive QuantiFERON assay) for diﬀ erent age 
groups and at diﬀ erent screening thresholds of incidence in country of origin
See Online for webappendix
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likely to be male than female (odds ratio [OR] 0·6, 95% CI 
0·5–0·9). Data for previous BCG vaccination were available 
for only 657 participants, of whom about 80% had been 
vaccinated. Screened immigrants most commonly 
originated from the Indian subcontinent and sub-Saharan 
Africa; Pakistan and India were the most common 
countries of origin (32% and 26%, respectively). Overall, 
the screened immigrants were broadly representative of 
the foreign-born population in the UK; however, our study 
population contained slightly more immigrants from the 
Indian subcontinent, and slightly fewer from sub-Saharan 
Africa than the national average.31
IGRA results were available for all participants. 
Overall, 245 individuals tested positive (20%, 95% CI 
18–22%), 982 were negative (80%, 77–82%), and two 
had indeterminate results (<1%, 0–1%). Participants 
attending the Westminster centre had a signiﬁ cantly 
lower proportion of IGRA-positive results than did 
those attending the Leeds and Blackburn centres 
(p=0·02). The proportions of positive immigrants aged 
less than 16 years, 16–25 years, and 26–35 years were 
19%, 15%, and 25%, respectively. In multivariate 
analysis, male sex, increasing age, and tuberculosis 
incidence in country of origin were associated with 
positive IGRA (table 1, ﬁ gure 2).
Table 2 outlines the outcomes of immigrant screening 
for latent infection stratiﬁ ed by age and incidence in the 
immigrants’ countries of origin. In all age groups, as the 
incidence threshold at which screening is instigated 
increases, fewer immigrants within the cohort are eligible 
to be screened and, consequently, the number of 
identiﬁ ed latent cases also decreases.
Application of NICE guidance to our cohort would 
result in 271 individuals out of 1229 (22%) being eligible 
for screening, of whom 72 (27%) were IGRA positive, 
representing 29% of all cases of latent infection. 
Decreasing the screening threshold for adults to 150 cases 
per 100 000 (with the threshold for individuals aged 
<16 years unchanged) increases the number of 
immigrants who are eligible for screening to 1049 (85%) 
of 1229 (p<0·0001), with a similar proportionate 
yield of 226 out of 1049 (22%) and signiﬁ cantly 
more latent cases identiﬁ ed (92%, p<0·0001) than with 
NICE guidance. 
Table 3 shows the results of the health-economic 
analysis, including the predicted number of tuberculosis 
cases and associated costs for each protocol in a cohort of 
10 000 immigrants over 20 years. Although strategies 
that used screening with IGRA were more expensive 
than no screening, they also resulted in fewer cases of 
active tuberculosis in the 20-years. Costs increased as 
the threshold of incidence in country of origin at which 
immigrants were eligible to be screened fell (table 3). 
Screening of all immigrants aged 35 years and under 
Cases of active 
tuberculosis 
over 20 years
Costs over 
20 years 
(2010 £)
Incremental cases of active 
tuberculosis prevented over 
20 years*
Incremental costs 
over 20 years† (£)
ICER (£ per tuberculosis 
case prevented)
No screening <16 year olds
Screen 0 16–35 year olds 95·4 608 370·0 Baseline Baseline Baseline
Screen <16 year olds, 40‡
Screen 16–35 year olds, 500 91·9 678 586·5 Extended dominance Extended dominance Extended dominance
Screen 16–35 year olds, 400 91·8 683 710·0 Strict dominance Strict dominance Strict dominance§
Screen 16–35 year olds, 450 91·7 683 267·9 Extended dominance Extended dominance Extended dominance¶
Screen 16–35 year olds, 350 90·8 697 208·7 Extended dominance Extended dominance Extended dominance
Screen 16–35 year olds, 300 87·1 761 431·6 Extended dominance Extended dominance Extended dominance
Screen 16–35 year olds, 250 83·4 823 312·8 12·0 214 942·8 17 956·0
Screen 16–35 year olds + sub-Saharan 
Africa, 500||
82·2 850 103·1 Extended dominance Extended dominance Extended dominance
Screen 16–35 year olds, 200 71·1 1 121 093·2 Extended dominance Extended dominance Extended dominance
Screen 16–35 year olds, 150** 54·2 1 431 928·5 29·2 608 615·7 20 818·8
Screen 16–35 year olds, 100 53·7 1 456 820·1 Extended dominance Extended dominance Extended dominance
Screen 16–35 year olds, 40 50·9 1 527 478·5 3·2 95 550·1 29 403·1
Screen all <16y
Screen all 16–35 year olds 50·9 1 532 256·6 0·0 4778·0 101 938·3
Arranged in order of increasing eﬀ ectiveness—ie, fewer cases of active tuberculosis for a hypothetical cohort of 10 000 immigrants over 20 years. When diﬀ erent strategies 
are ranked from least eﬀ ective to most eﬀ ective (ie, number of cases of active tuberculosis that are predicted to occur), the incremental cost-eﬀ ectiveness ratios (ICER) of 
most screening options, including present National Institute for Health and Clinical Excellence (NICE) guidance, are excluded through extended dominance. *Incremental 
number of cases are calculated as the diﬀ erence (ie, number of cases prevented) from the previous non-dominated option. †Incremental costs are calculated as the diﬀ erence 
(ie, extra £) from the previous non-dominated option. ‡Incidence per 100 000 per year. §Strict dominance—by which a particular screening threshold is both less eﬀ ective 
and more expensive than the next most eﬀ ective screening threshold. ¶Extended dominance—by which the ICER for a particular screening threshold is higher than for the 
next most eﬀ ective strategy (screening threshold), therefore, the higher ICER is removed from the cost-eﬀ ectiveness analysis. ||Represents the situation occurring if screening 
is done by UK national (NICE) guidance. **The situation occurring if screening included immigrants from the Indian subcontinent.
Table 3: Projected cases of active tuberculosis and associated costs with screening immigrants at diﬀ erent thresholds of tuberculosis incidence
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from any countries irrespective of tuberculosis incidence 
would cost more than £1·5 million and prevent 
44·5 cases of tuberculosis, whereas application of NICE 
guidance would cost about £850 000 and prevent 
13·2 cases of active disease. Although no immigrant 
screening for latent tuberculosis infection was the least 
expensive option (£600 000), it resulted in the most cases 
of active tuberculosis.
After exclusion of dominated strategies (table 3), four 
cost-eﬀ ective strategies remained. In decreasing order of 
cost-eﬀ ectiveness, these strategies were (in addition to 
screening immigrants younger than 16 years from 
countries ≥40/100 000) to screen 16–35 year olds from 
countries with incidences of 250 per 100 000 and higher, 
150 per 100 000 and higher, and more than 40 per 100 000. 
The fourth strategy was to screen all individuals aged 
35 years and younger from all countries irrespective of 
tuberculosis incidence. The associated ICERs were 
£17 956·0, £20 818·8, £29 403·1, and £101 938·3, 
respectively, per active case averted. Therefore, for ICERs, 
the most cost-eﬀ ective strategies would be to start 
screening at 40 cases per 100 000 for individuals aged less 
than 16 years, and 250 per 100 000 for 16–35 year olds. 
However, the ICER for the next most cost-eﬀ ective 
strategy (screening individuals aged less than 16 years at 
40 per 100 000 and 16–35-year-olds at 150 per 100 000) was 
only just under £3000 higher than the most cost-eﬀ ective 
strategy. Strategies to further reduce the threshold to 
include screening all immigrants aged 35 years and 
younger from countries with incidences of 40 cases per 
100 000 and higher, or indeed all immigrants, were both 
non-dominated options; however, the associated ICERs 
were very high.
Numbers needed to screen and numbers needed to 
treat (NNT) ranged from 165·5 to 231·9 and 42·0 to 42·7 
respectively. Screening 16–35-year-olds at 250 per 100 000 
had the lowest NNT (42·0), whereas screening at a 
threshold higher than this value generally resulted in a 
higher NNT.
Table 4 and webappendix (p 10–11) show results of the 
univariate sensitivity analysis. Changing several of the 
variables aﬀ ected estimates for the ICERs of each of the 
strategies but did not signiﬁ cantly aﬀ ect the rank order of 
the most cost-eﬀ ective strategies. The most important 
variables were the rate at which new-entrants progress to 
active tuberculosis and the prevalence of latent 
tuberculosis in the screened cohort. Increased values for 
both variables increased cost-eﬀ ectiveness (ie, lower 
ICERs). Cost-eﬀ ectiveness was signiﬁ cantly more aﬀ ected 
by diagnostic speciﬁ city than by sensitivity. Reductions in 
speciﬁ city increased ICER estimates (ie, reduced cost-
eﬀ ectiveness) because more false-positive, uninfected 
Point 
estimate
Range 
explored
<16 years >40*
16–35 years >250
<16 years >40
16–35 years >150
<16 years >40
16–35 years >40
Screen all <16 years
Screen all 16–35 years
Prevalence of latent tuberculosis infection 0·22 0·1
0·4
28 853·7
14 527·9
36 319·9
16 081·0
61 481·5
20 650·3
136 739·3
73 864·9
Sensitivity of IGRA 0·84 0·78
0·90
17 932·7
17 973·1
20 788·3
20 841·2
29 442·5
29 374·3
86 066·0
117 507·2
Speciﬁ city of IGRA 0·99 0·88
1·00
29 372·8
17 365·2
50 789·5
19 751·4
SD
26 108·0
SD
272 290·5
Proportion progressing to active tuberculosis (over 
20 years)
0·05 0·025
0·15
41 823·6
2049·3
47 494·4
3 040·8
64 498·4
6 013·6
208 178·6
31 133·8
Number of contacts 6·5 3·25
10
19 522·5
16 269·0
22 385·3
19 131·8
30 969·6
27 716·1
103 504·8
100 251·3
Eﬃ  cacy of complete chemoprophylaxis (RR %) 0·65 0·5
0·8
24 772·0
13 587·3
28 418·9
15 943·5
39 717·1
22 860·8
161 114·4
85 522·9
Eﬀ ectiveness of partial chemoprophylaxis (RR %) 0·21 0·1
0·3
18 654·1
17 413·2
21 597·6
20 213·3
30 453·4
28 587·3
99 352·9
104 149·4
Proportion starting chemoprophylaxis 0·95 0·3
1·0
60 149·2
16 985·3
68 786·9
19 710·9
SD
27 841·5
98 102·9
107 085·1
Proportion of individuals completing 
chemoprophylaxis
0·85 0·3
1·0
32 756·6
15 836·0
37 561·9
18 417·1
53 089·1
26 072·5
554 774·1
91 930·3
Number of secondary cases of active tuberculosis per 
index case
0·2 0·1
0·3
20 162·9
16 088·1
23 285·6
18 731·1
32 648·9
26 655·9
111 673·0
93 539·9
Number of secondary cases of latent tuberculosis cases 
per index case
0·18 0·09
0·27
17 983·4
17 928·6
20 848·5
20 789·3
29 439·3
29 366·9
102 030·7
101 846·0
Proportion of active cases admitted as inpatient 0·53 0·265
0·795
19 019·4
16 892·6
21 882·3
19 755·4
30 466·5
28 339·6
103 001·7
100 874·9
Proportion of immigrants receiving chemoprophylaxis 
who developed drug-induced liver injury
0·002 0·001
0·003
17 944·4
17 967·6
20 808·4
20 829·2
29 396·1
29 410·0
101 895·2
101 981·5
Only non-dominated options are presented. The ﬁ gures presented are the incremental cost-eﬀ ectiveness ratios (ICERs). Increasing ICER indicates decreasing cost-eﬀ ectiveness. *Incidence per 100 000 per year. 
IGRA=interferon-γ release assay. SD=strict dominance. RR=risk reduction.
Table 4: Univariate sensitivity analysis of the probabilities and proportions that were used as input variables in the decision model
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individuals would be treated unnecessarily. Reductions 
in screening costs for latent infection, or assessment of 
those who screened positive, signiﬁ cantly reduced ICER 
values (ie, increased cost-eﬀ ectiveness).
Discussion
Our assessment of the outcomes and cost-eﬀ ectiveness 
of immigrant screening with IGRA at diﬀ erent incidence 
thresholds showed that new entrants to the UK have a 
high prevalence of latent infection, which varies by age, 
sex, and tuberculosis incidence in their country of origin 
(panel 2). UK national guidance for which groups to 
screen excludes most immigrants with latent infection, 
and our analysis suggests that policy could be modiﬁ ed 
in centres undertaking or considering the implementation 
of one-step IGRA testing to substantially reduce 
tuberculosis incidence while remaining cost eﬀ ective.
In our cohort, the prevalence of latent infection was 
moderately high at 20%. Past studies from various 
settings, which used tuberculin skin test to diagnose 
latent infection recorded 34–55% of immigrants to be 
skin-test-positive.37–40 These high proportions are likely to 
show cross reactivity of past vaccination with BCG, 
resulting in many false-positive skin-test results.34 
Therefore, the main implication of screening with the 
skin test is that an increased number of uninfected 
individuals will be unnecessarily treated with 
chemoprophylaxis. However IGRAs, which have a high 
speciﬁ city in BCG-vaccinated patients, result in fewer 
false-positives than occur with tuberculin skin tests and, 
therefore, might provide a reduced, but accurate, 
estimated prevalence of latent infection in immigrants.34 
Data for the burden of latent infection diagnosed by 
IGRA in immigrants are scarce and relate generally to 
immigrant tuberculosis contacts or undocumented 
immigrants.15,37,40–42 These studies from various parts of 
Europe, including the UK, have suggested that 15–38% 
of new entrants have positive IGRA results.
Immigrants to the UK (other than from within the EU) 
arrive largely from countries with the highest burdens of 
tuberculosis.5 In our cohort, about 81% of all screened 
immigrants and just less than 87% of all cases of latent 
infection were from the Indian subcontinent and sub-
Saharan Africa. However, by including several UK centres 
with diﬀ erent patterns of migration, we provide reliable 
estimates for the prevalence of latent infection in 
immigrants arriving from countries with a wide range of 
tuberculosis burden. Prevalence of latent infection was 
correlated independently with tuberculosis incidence in 
the immigrants’ country of origin. No immigrants from 
countries with incidences less than 50 cases per 100 000 
had a positive IGRA; a ﬁ nding that is consistent with 
small-scale European studies that used only a binary 
classiﬁ cation of incidence less than or greater than 
50 cases per 100 000.37,41,42
Increased age was also independently associated with 
an increased likelihood of a positive IGRA result.43 
Although past work from both developed and developing 
countries has shown that IGRA positivity correlates with 
increasing age,44–46 with no prospective data, whether this 
correlation represents a truly higher prevalence of latent 
infection (due to more cumulative exposure in settings 
with high burdens of tuberculosis) or suboptimum 
IGRA-sensitivity in younger individuals is unclear.47
Evidence has shown that many areas of the UK do not 
follow national guidelines for screening of latent infection 
and have set their own criteria for screening, and, indeed, 
our data suggest that NICE’s 2006 cutoﬀ  in 16–35-year-olds 
might be too high and restrictive.13,15 If we applied national 
guidance (which has been in place since 2006) in our 
cohort to those aged 35 years and younger, only 29% of 
latent infections would be identiﬁ ed, leaving nearly three-
quarters (mostly those from the Indian subcontinent) 
undiagnosed and at risk of developing active disease and 
possibly infecting others. Indeed, these immigrants from 
the Indian subcontinent constitute the largest proportion 
of foreign-born patients with tuberculosis in the UK.8 If 
the threshold incidence in the country of origin for 
screening 16–35-year-olds were reduced to 150/100 000, 
92% of those with latent infections would be identiﬁ ed, 
leaving only a small fraction undiagnosed and at risk of 
developing active disease. 
Our health-economic analysis indicated that for one-
step IGRA screening of 16–35 year-olds, four incidence 
thresholds were cost eﬀ ective, and all were more cost 
eﬀ ective than the threshold that is currently recommended 
by national guidance. The two most cost-eﬀ ective 
strategies were to screen at 250/100 000 and higher (with 
an ICER of £17 956·0 per tuberculosis case averted) and 
to screen at 150/100 000, which would avert an additional 
Panel 2: Research in context
Systematic review
We searched Medline from 1960 to 2010 for studies 
assessing the cost-eﬀ ectiveness of one-step IGRA-based 
screening for latent-tuberculosis infection in immigrants to 
high-income countries. There were no published studies that 
used IGRA testing to parameterise a health-economic model 
with the speciﬁ c aim of deﬁ ning the most cost-eﬀ ective 
tuberculosis incidence threshold. 
Interpretation
Our ﬁ ndings indicate that immigrants arriving in the UK, who 
originate from mostly countries with high burdens of 
tuberculosis, have a high prevalence of latent tuberculosis 
infection, which is strongly associated with the incidence of 
tuberculosis in their countries of origin. Current guidelines 
miss most imported cases of latent tuberculosis but screening 
for latent infection can be cost-eﬀ ectively implemented at an 
incidence threshold that identiﬁ es most immigrants with 
latent infection, thereby preventing substantial numbers of 
future cases of active tuberculosis.
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29·2 cases of active disease per 10 000 immigrants 
(compared to screening at ≥250/100 000) at a marginally 
increased ICER of £20 818·8 per each additional case 
averted. This second strategy would encompass 
individuals from many Asian countries who are currently 
excluded, including those from the Indian subcontinent 
who form a large proportion of immigrants to the UK.4 
Further reduction of the threshold to 40 cases per 100 000 
or even lower (ie, screening all immigrants) would prevent 
further cases of active infection; however, starting 
screening at these reduced thresholds would incur 
substantially increased total costs—therefore, resource 
availability and the funds that policy makers are willing to 
spend to control the incidence of active tuberculosis 
would need to be reconsidered.
Past health-economic analyses compared tuberculin 
skin-test with chest radiography for screening new-
entrants from countries with high burdens of tubercu-
losis (especially for active tuberculosis).48,49 Although 
Schwartzman and colleagues48 reported that screening 
with chest radiographs was more cost eﬀ ective than with 
skin tests, this conclusion might not be universally 
relevant because the investigators assumed that most 
unscreened immigrants developing active disease would 
need prolonged in-patient management. By contrast, 
Dasgupta and colleagues49 noted that screening and 
treatment of immigrants for latent infection in a subset 
who had undergone chest radiography and skin tests had 
important public health eﬀ ects, but would be expensive 
because of poor programme eﬃ  ciency (eg, the proportion 
of immigrants completing chemoprophylaxis). Oxlade 
and colleagues50 have compared several scenarios of 
immigrant screening, including chest radiography, 
tuberculin skin test, and IGRAs, and shown that all 
techniques had a modest eﬀ ect on tuberculosis 
notiﬁ cations; chest radiography alone was the most cost-
eﬀ ective option. However, the model was based on 
putative scenarios rather than on actual data, and assumed 
a very low prevalence of latent infection in new immigrants 
(0·08–2·1%) and a low rate of reactivation. Our study 
advances the evidence base by using unique, accurate, 
and empirical IGRA screening data from various centres 
to objectively apply parameters to a decision model for 
assessing the key question of yields and cost-eﬀ ectiveness 
of immigrant screening at diﬀ erent levels of incidence.
Although we chose a conservative progression rate 
from latent tuberculosis to active tuberculosis, of 5% over 
20 years, this rate remains poorly understood. Marks and 
colleagues51 calculated a progression rate of 6·7% over 
40 years in tuberculosis skin-test-positive (>15 mm) 
refugees from southeast Asia.47 However, data from the 
UK,52 in a population similar to ours, suggest that over 
10-years, about 13% of skin-test-positive, untreated 
immigrants (mostly from the Indian subcontinent) 
progress to active tuberculosis. These data mean that our 
results probably underestimate the true cost-eﬀ ectiveness. 
Further work should ascertain whether the actual rates of 
disease progression in IGRA-positive immigrants after 
arrival and, speciﬁ cally, whether this rate diﬀ ers according 
to age and country of origin.
The success of screening will depend on implementation 
of robust systems, which will allow immigrants to be 
identiﬁ ed in a timely fashion; however, the overall eﬀ ect 
of screening will be largely determined by patient and 
physician adherence both to having the diagnostic test, 
and to completing the chemoprophylactic drug regimen. 
A more speciﬁ c blood test (ie, IGRA) might increase 
compliance in immigrants compared to two visits for 
skin tests, which are frequently false positive in this 
BCG-vaccinated population.22,34
Our work had several limitations. Routine surveillance 
data are likely to under report the prevalence of infection, 
whereas any selection bias in which immigrants attended 
for screening could increase the prevalence of latent 
infection in our study. Moreover, we did not have 
concurrent results for tuberculin skin test against IGRA 
because the participating centres do not routinely do skin 
tests in new-entrants. One of the most substantial obstacles 
with test performance is the scarcity of a gold-standard 
test for latent tuberculosis, which makes it diﬃ  cult to 
calculate the sensitivity of diagnostic tests for this infection. 
We therefore used ﬁ gures from the most up-to-date meta-
analysis of IGRA performance in which culture-conﬁ rmed 
active tuberculosis was the surrogate reference standard.22 
Because IGRA sensitivity is likely to be lower in patients 
with active tuberculosis than in healthy individuals 
undergoing screening for latent infection, this assumption 
might underestimate the sensitivity of the test and 
therefore the cost-eﬀ ectiveness estimates. By contrast, if 
speciﬁ city estimates are based on preselected patients 
with a very low probability of tuberculosis, the test 
speciﬁ city might be overestimated. Increased estimates 
would give fewer false-positive results, thereby 
overestimating the cost-eﬀ ectiveness of screening.
In our health-economic analysis we made some 
assumptions about the natural history of tuberculosis (eg, 
onward transmission to contacts and complete clearance 
of infection, with no risk of reinfection after 
chemoprophylaxis) because this was not a formal dynamic 
model that would allow us to capture the intrinsic 
transmission dynamics of tuberculosis. Although we 
included secondary cases of active and latent tuberculosis, 
incorporation of tertiary and quaternary cases would 
further increase cost-eﬀ ectiveness. Moreover, we did not 
incorporate drug-resistant strains or HIV infection. 
Although data from our study parameterised the model, 
uncertainty surrounds several variables for which we 
made assumptions—eg, we assumed that there were no 
prevalent cases of active tuberculosis in the screened 
cohort, but, in reality, a small proportion of individuals 
proved to have active disease as a result of screening. By 
not incorporating these factors into the decision-analysis, 
our analysis could underestimate the cost-eﬀ ectiveness of 
screening. By contrast, we assumed that all patients with 
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active disease would be diagnosed, accept, and complete, 
treatment, and this assumption could result in 
overestimation of cost-eﬀ ectiveness.
Unlike NICE’s cost-utility analysis in which assessments 
of diﬀ erent strategies are made using cost per quality-
adjusted life-year, like other investigators, we assessed 
eﬀ ectiveness as cost per tuberculosis case prevented,48,50,53,54 
because objective data on quality-adjusted life-years are 
still scarce for patients with active tuberculosis and for 
those receiving chemoprophylaxis.
As national guidelines are developed for screening of 
latent tuberculosis with new techniques (such as IGRA), 
they will need to quantitatively integrate the prevalence 
of latent infection in immigrant populations from 
diﬀ erent regions to formulate policy that cost-eﬀ ectively 
improves tuberculosis control and prevention.55 Finally, 
although we assessed the cost-eﬀ ectiveness of screening 
at diﬀ erent thresholds with one-step IGRA, further work 
should compare diﬀ erent screening protocols (such as 
skin test with IGRA vs skin-test alone vs IGRA alone) and 
diﬀ erent IGRA tests (QuantiFERON-TB Gold In-Tube vs 
T-SPOT.TB vs next-generation IGRA).34,56–59
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